| 30792533 |
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Serrano, C,
Mariño-Enríquez, A,
Tao, DL,
Ketzer, J,
Eilers, G,
Zhu, M,
Yu, C,
Mannan, AM,
Rubin, BP,
Demetri, GD,
Raut, CP,
Presnell, A,
McKinley, A,
Heinrich, MC,
Czaplinski, JT,
Sicinska, E,
Bauer, S,
George, S,
Fletcher, JA
|
Br. J. Cancer |
2019 |
| 16397263 |
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Schittenhelm, MM,
Shiraga, S,
Schroeder, A,
Corbin, AS,
Griffith, D,
Lee, FY,
Bokemeyer, C,
Deininger, MW,
Druker, BJ,
Heinrich, MC
|
Cancer Res. |
2006 |
